Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics


Ultragenyx Pharmaceutical Inc. (RARE)

Today's Latest Price: $73.81 USD

3.32 (4.71%)

Updated May 22 4:00pm

Add RARE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

RARE Stock Summary

  • For RARE, its debt to operating expenses ratio is greater than that reported by merely 9.65% of US equities we're observing.
  • With a price/sales ratio of 36.19, Ultragenyx Pharmaceutical Inc has a higher such ratio than 95.65% of stocks in our set.
  • Revenue growth over the past 12 months for Ultragenyx Pharmaceutical Inc comes in at 106.56%, a number that bests 94.89% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RARE, based on their financial statements, market capitalization, and price volatility, are RGNX, APTX, FPRX, MEIP, and AGIO.
  • RARE's SEC filings can be seen here. And to visit Ultragenyx Pharmaceutical Inc's official web site, go to www.ultragenyx.com.
RARE Daily Price Range
RARE 52-Week Price Range

RARE Stock Price Chart More Charts


RARE Price/Volume Stats

Current price $73.81 52-week high $76.00
Prev. close $70.49 52-week low $31.99
Day low $70.20 Volume 482,991
Day high $74.08 Avg. volume 581,472
50-day MA $56.19 Dividend yield N/A
200-day MA $50.03 Market Cap 4.40B

Ultragenyx Pharmaceutical Inc. (RARE) Company Bio


Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.


RARE Latest News Stream


Event/TimeNews Detail
Loading, please wait...

RARE Latest Social Stream


Loading social stream, please wait...

View Full RARE Social Stream

Latest RARE News From Around the Web

Below are the latest news stories about Ultragenyx Pharmaceutical Inc that investors may wish to consider to help them evaluate RARE as an investment opportunity.

Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy?

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | April 27, 2020

Ultragenyx Inks Deal With Daiichi For Gene Therapy Platform While Also Extending Cash Runway

Biopharma Ultragenyx (RARE), which focuses on rare and ultra-rare diseases, has announced a key strategic partnership with Japanese global pharma Daiichi Sankyo.The deal grants Daiichi a non-exclusive license to RARE’s HeLa PCL and HEK293 mammalian cell AAV manufacturing system. Ultragenyx’s HeLa producer cell line (PCL) platform is intended to enable large scale AAV-based gene therapy product manufacturing that is highly reproducible, more consistent, and less expensive than other gene therapy manufacturing platforms.In return, RARE will receive $125M cash and $75M equity (at $60/ share) upfront, $25M upon completion of tech transfer, and single-digit royalties on net sales of future products. The company is currently trading at $44/ share.Crucially, RARE retains an option to co-develo...

Yahoo | April 1, 2020

Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology

Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced a strategic partnership and non-exclusive license and technology access agreement with Daiichi Sankyo Company, Limited for Ultragenyx’s proprietary AAV-based gene therapy manufacturing technologies. Ultragenyx’s HeLa producer cell line (PCL) platform enables large commercial-scale AAV-based gene therapy product manufacturing that is intended to be highly reproducible, more consistent, and less expensive than other gene therapy manufacturing platforms.

Yahoo | April 1, 2020

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced a new exclusive, worldwide license agreement, extending the companies’ existing gene therapy partnership. Under the terms of the agreement, REGENXBIO has granted Ultragenyx an exclusive, worldwide license, with rights to sublicense, to REGENXBIO’s NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder.

Yahoo | March 31, 2020

Hedge Funds Were Selling Ultragenyx Pharmaceutical Inc (RARE) Before The Coronavirus

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

Yahoo | March 29, 2020

Read More 'RARE' Stories Here

RARE Price Returns

1-mo 11.44%
3-mo 34.69%
6-mo 87.84%
1-year 29.08%
3-year 32.02%
5-year -14.91%
YTD 72.82%
2019 -1.77%
2018 -6.25%
2017 -34.03%
2016 -37.32%
2015 155.65%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9118 seconds.